Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for...
October 13 2020 - 8:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced today that clinical data from
its NeuroStar Outcomes Registry, which suggests NeuroStar Advanced
Therapy be evaluated as a first-line treatment for Major Depressive
Disorder (MDD), will be published in the December 2020 print issue
of the Journal of Affective Disorders and is available online now.
The NeuroStar Outcomes Registry launched in November 2016 for
the purpose of collecting and analyzing outcomes data from
treatment in real-world clinical settings with Neuronetics’
NeuroStar Advanced Therapy, a non-drug, non-invasive option for
treating depression. Since its launch, it has grown into the
largest registry focused on outcomes for depression treatment.
The study authors found that treatment with NeuroStar Advanced
Therapy showed robust antidepressant effects, greater than in early
open-label studies of transcranial magnetic stimulation (TMS). The
clinical benefit from NeuroStar Advanced Therapy reported by both
patients and clinicians in routine clinical practice compared
favorably with alternative interventions for treatment-resistant
depression. The authors analyzed two sample sets of more than 5,000
patients across 103 practice sites, evaluating patient-rated and
clinician-rated clinical outcomes data from treatment with
NeuroStar. The research further validates efficacy results shown in
a prior naturalistic study, which showed a 58 percent response rate
and 37 percent remission rate on the CGI-S scale.1
“Research from the Outcomes Registry continues to demonstrate
that NeuroStar Advanced Therapy is a safe and effective treatment
for those with depression who haven’t benefited from antidepressant
medications, and we’re excited by the opportunity to share this
research published in the Journal of Affective Disorders with the
broader clinical community,” said Dr. Harold A. Sackeim, Professor
of Clinical Psychology in Psychiatry and Radiology at the Vagelos
College of Physicians and Surgeons, Columbia University and lead
author of the study. “The research demonstrates that NeuroStar
Advanced Therapy can transform lives of many patients struggling
with treatment-resistant depression and provides physicians with
the scientific evidence needed to optimize the treatment of
patients with depression.”
Study highlights include:
- Self-reported and clinician ratings showed robust
antidepressant effects from NeuroStar Advanced Therapy, greater
than those in early open-label studies of TMS
- Strong efficacy and the low side effect and medical risk
profile suggest that NeuroStar Advanced Therapy be evaluated as a
first-line treatment for Major Depressive Disorder
- Efficacy did not decline with age, and motor threshold was also
unrelated to antidepressant effects
- Patients who received a larger number of pulses per session had
superior outcomes
- Females responded more favorably to treatment than males by
5-10%
- Remission rates were notably high (27.9% to 57.8%) in both the
Intent-to-Treat sample (N=5010) and the Completer sample
(N=3814)
- Response rates were notably high across self-report and
clinician-administered assessments in the Completer sample
(N-3,814)
“At a time when many are struggling with depression and facing
the unprecedented challenges of the COVID-19 pandemic, this
promising data from the Outcomes Registry underscores the
importance of innovative and effective depression treatments like
NeuroStar,” said Keith J. Sullivan, President and CEO of
Neuronetics. “It is incredible to see how far the Outcomes Registry
has progressed, not only providing real-world insights and best
practices that advance the treatment of MDD, but also staying true
to our mission of renewing lives by transforming neurohealth.”
The Journal of Affective Disorders is a peer-reviewed medical
journal of the International Society for Affective Disorders that
publishes papers and cutting-edge research on multiple aspects of
affective disorders, including biochemistry, pharmacology,
genetics, statistics, clinical studies, and studies of treatments.
The Outcomes Registry publication is available online here and will
be published in the December 2020 print edition, Volume 277 of the
Journal of Affective Disorders.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.
Media Contact: Meagan DominickVault
Communications610-455-2779mdominick@vaultcommunications.com
1 Carpenter LL, et al. Depress Anxiety, (2012)
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Sep 2023 to Sep 2024